Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

This study tests whether growth hormone replacement therapy can improve quality of life, cognitive function, and other outcomes in veterans who sustained a mild traumatic brain injury (mTBI) during military service and now have adult growth hormone deficiency (AGHD). Brain injuries can damage the pituitary gland — the brain's hormone control center — leading to growth hormone deficiency that causes fatigue, cognitive difficulties, reduced quality of life, and other symptoms. Replacing growth hormone in this population may help address these lasting effects of combat injury. Veterans of OEF/OIF/OND who have both confirmed mTBI (from service) and growth hormone deficiency will be randomly assigned to receive recombinant human growth hormone (rhGH) or placebo. Outcomes including quality of life, cognitive performance, mood, and physical function will be tracked over time. You may be eligible if: - You are an OEF/OIF/OND veteran, aged 21–55 - You sustained one or more mTBIs during military service at least 12 months ago - You have confirmed growth hormone deficiency (by macimorelin test and IGF-I level) - Your quality of life is significantly impacted (QoL-AGHDA score ≥11) - Your medications and hormones have been stable for at least 3–4 weeks You may NOT be eligible if: - You have a history of moderate or severe TBI - You have bipolar disorder, schizophrenia, or active suicidal ideation - You have active cancer, severe infection, or other serious illness - Your BMI is above 35 or you weigh more than 350 lbs - You are a woman of childbearing potential not using contraception - You are currently using growth hormone or related hormones Talk to your doctor to see if this trial is right for you.